Stoky
Back to explore
N
NoahListening
A
AshListening
0:00 / 0:00I. Quarterly Financial Performance and Results of Operations
COR logo

Cencora Revenue Hits $84.4 Billion Driven by 11% Surge in GLP-1 Sales

COR10-QFiling Date: 2/4/2026
Cencora, Inc.
Description

What this story covers

Cencora’s Q1 2026 report highlights a 5.5% revenue increase to $84.4 billion, fueled by GLP-1 drug demand and specialty healthcare growth. Despite a $249.5 million impairment and $4.3 billion in opioid liabilities, strategic acquisitions signal a pivot toward high-margin specialty distribution.

Story snapshot

CompanyCencora, Inc.
TickerCOR
VariantStandard detailed
Duration18:44
Filing type10-Q
PeriodQ1 2026
IndustryHealthcare & Pharmaceuticals
Accession0001140859-26-000006
Sources1

Full Story Script

Content not available for this story.

Primary Sources

sec_filing10-QView on SEC.gov →

Ask Noah

Question the story, source filings, and key financial signals.

Sign in to chat with Noah

Ask questions about revenue, margins, risk factors, filings and more. Noah uses retrieval-augmented analysis over raw financial disclosures.

Sign in